Editorial: Metastatic hormone-sensitive prostate cancer: new therapeutic strategies to improve patient outcome.
作者信息
Chinen Ludmilla T D, Sadi Marcus V
机构信息
Hcor, Associação Beneficente Siria, São Paulo, Brazil.
Hospital Amaral Carvalho, Jau, São Paulo, Brazil.
出版信息
Front Oncol. 2025 Apr 9;15:1589694. doi: 10.3389/fonc.2025.1589694. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Metastatic hormone-sensitive prostate cancer: new therapeutic strategies to improve patient outcome.
Front Oncol. 2025 Apr 9;15:1589694. doi: 10.3389/fonc.2025.1589694. eCollection 2025.
2
PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC).
Clin Transl Oncol. 2025 Feb;27(2):706-715. doi: 10.1007/s12094-024-03625-y. Epub 2024 Jul 29.
3
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
4
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort.
Prostate. 2025 Jul;85(10):912-918. doi: 10.1002/pros.24898. Epub 2025 Apr 8.
5
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Cochrane Database Syst Rev. 2014 Jun 30;2014(6):CD009266. doi: 10.1002/14651858.CD009266.pub2.
6
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
BJU Int. 2015 Jul;116(1):30-6. doi: 10.1111/bju.13026. Epub 2015 Mar 23.
7
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3.
8
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer.
Expert Opin Pharmacother. 2023 Sep-Dec;24(16):1765-1774. doi: 10.1080/14656566.2023.2244415. Epub 2023 Aug 7.
9
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Int J Clin Oncol. 2025 Mar;30(3):539-550. doi: 10.1007/s10147-024-02676-z. Epub 2024 Dec 10.
10
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor.
Int J Clin Oncol. 2024 Dec;29(12):1946-1958. doi: 10.1007/s10147-024-02637-6. Epub 2024 Oct 1.
本文引用的文献
1
Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
BJU Int. 2025 Mar;135(3):408-421. doi: 10.1111/bju.16577. Epub 2024 Nov 12.
2
Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
Actas Urol Esp (Engl Ed). 2020 Dec;44(10):692-700. doi: 10.1016/j.acuro.2020.08.001. Epub 2020 Oct 1.
3
Development and prevalence of castration-resistant prostate cancer subtypes.
Neoplasia. 2020 Nov;22(11):566-575. doi: 10.1016/j.neo.2020.09.002. Epub 2020 Sep 25.
4
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
Circulation. 2016 Feb 2;133(5):537-41. doi: 10.1161/CIRCULATIONAHA.115.012519.
Zotero 插件